Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Thoracic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Hepatocellular 131Liver Neoplasms 42Carcinoma, Renal Cell 36Leukemia, Myeloid, Acute 32Neoplasm Metastasis 26Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 22Kidney Neoplasms 16Neoplasms 14Prostatic Neoplasms 12Pancreatic Neoplasms 12Recurrence 11Lung Neoplasms 11Colorectal Neoplasms 10Sarcoma 9Melanoma 9Brain Neoplasms 9Myelodysplastic Syndromes 8Glioblastoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Urinary Bladder Neoplasms 5Thyroid Neoplasms 5Rectal Neoplasms 5Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Stomach Neoplasms 4Ovarian Neoplasms 4Liver Diseases 4Gliosarcoma 4

Interventions

Cisplatin 141Radiotherapy 115Cetuximab 95Docetaxel 69Radiotherapy, Intensity-Modulated 55Carboplatin 47pembrolizumab 46Surveys and Questionnaires 46Paclitaxel 41Fluorouracil 39Radiation 29Blood Specimen Collection 27Drug Therapy 26Erlotinib Hydrochloride 23Nivolumab 21Surgical Procedures, Operative 17Standard of Care 16Magnetic Resonance Spectroscopy 16Radiosurgery 14Pemetrexed 14Gemcitabine 14Everolimus 13Celecoxib 13durvalumab 12Low-Level Light Therapy 12Immunohistochemistry 12Cyclophosphamide 12Capecitabine 12Amifostine 12Chemoradiotherapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Head and Neck Neoplasms × Sorafenib × Clear all
NCT00703638 2017-11-29

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
16 enrolled
BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT00199160 2015-05-20

Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck Cancer

Jules Bordet Institute

Phase 2 Completed
60 enrolled
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡